RGBP (Regen BioPharma) Shiller PE Ratio: (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regen BioPharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regen BioPharma  (OTCPK:RGBP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Regen BioPharma Shiller PE Ratio Related Terms


Regen BioPharma Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Regen BioPharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma Shiller PE Ratio Chart

Regen BioPharma Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Regen BioPharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RGBP vs IOBTQ, SCPX, LIPO: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Regen BioPharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Shiller PE Ratio falls into.



Regen BioPharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Regen BioPharma's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Regen BioPharma's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/333.9520*333.9520
=0.000

Current CPI (Jun. 2026) = 333.9520.

Regen BioPharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -5.400 241.428 -7.469
201612 -2.925 241.432 -4.046
201703 -6.975 243.801 -9.554
201706 -14.250 244.955 -19.427
201709 -7.275 246.819 -9.843
201712 -14.625 246.524 -19.812
201803 -5.850 249.554 -7.828
201806 -0.525 251.989 -0.696
201809 -4.350 252.439 -5.755
201812 0.525 251.233 0.698
201903 -0.825 254.202 -1.084
201906 -38.550 256.143 -50.260
201909 2.347 256.759 3.053
201912 2.250 256.974 2.924
202003 -1.950 258.115 -2.523
202006 1.200 257.797 1.554
202009 0.525 260.280 0.674
202012 0.587 260.474 0.753
202103 0.150 264.877 0.189
202106 -1.575 271.696 -1.936
202109 -0.188 274.310 -0.229
202112 0.750 278.802 0.898
202203 -11.020 287.504 -12.800
202206 9.555 296.311 10.769
202209 -0.005 296.808 -0.006
202212 0.225 296.797 0.253
202303 -0.015 301.836 -0.017
202306 -0.015 305.109 -0.016
202309 -0.050 307.789 -0.054
202312 -0.020 306.746 -0.022
202403 -0.015 312.332 -0.016
202406 -0.015 314.175 -0.016
202409 -0.030 315.301 -0.032
202412 -0.065 315.605 -0.069
202503 0.000 319.799 0.000
202506 -0.010 322.561 -0.010
202509 -0.020 324.800 -0.021
202512 -0.010 324.054 -0.010
202603 0.000 330.213 0.000
202606 0.000 333.952 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regen BioPharma Business Description

Other Exchanges RGBPP.PFD:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.